Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

US pharma market

- PMLiVE

Sandoz biosimilar receives EC approval to treat MS

Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

- PMLiVE

Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria

ABP 959 demonstrated no ‘clinically meaningful’ difference to the reference product in the phase 3 study

- PMLiVE

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

Cimerli belongs to the anti-VEGF therapy class of biologics that has helped retinal patients maintain or gain vision

- PMLiVE

Sandoz’s application for MS biosimilar accepted by FDA

The proposed ‘first-of-a-kind’ biosimilar matched the reference medicine, Biogen’s Tysabri, in terms of efficacy, safety and immunogenicity

- PMLiVE

The US celebrates five years of biosimilars on the market – a look to the past, present and future

Why the success of biosimilars in the US has been mixed

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Sandoz finally wins FDA approval for Neulasta biosimilar

Follows a three year wait since initial rejection in 2016

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Boehringer claims EU okay for Humira biosimilar

But won’t launch before expiration of the respective SPC for adalimumab in October 2018

- PMLiVE

Sandoz says Humira biosimilar clears clinical hurdle

Its drug matches the safety and efficacy of AbbVie’s plaque psoriasis blockbuster

- PMLiVE

NOR-SWITCH – the final piece in the biosimilar puzzle?

As more biosimilars become available globally, physicians, payers and patients alike are keen to understand the safety of switching

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links